Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...

In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Protara Therapeutics (TARA – Research ...

In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Molecular Partners (MOLN – Research ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $30.00. The company’s shares clo ...

Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to ...

II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) ...

Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a ...

Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Immunome (NasdaqCM:IMNM) with a Outperform ...

On March 16, Barcelona will host its bigger marathon yet, with a record of 27,000 runners racing through the most emblematic spots. The 46th edition of the Zurich Marató Barcelona 2025 has sold ...

GLEN ALLEN, Va., February 20, 2025--(BUSINESS WIRE)--Dynex Capital, Inc. announced today the Company’s Board of Directors has declared a cash dividend of $0.17 per share on its Common Stock ...